X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs PFIZER - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD PFIZER WYETH LTD/
PFIZER
 
P/E (TTM) x 27.7 36.1 76.8% View Chart
P/BV x 5.3 5.3 100.8% View Chart
Dividend Yield % 1.3 0.6 198.3%  

Financials

 WYETH LTD   PFIZER
EQUITY SHARE DATA
    WYETH LTD
Mar-13
PFIZER
Mar-18
WYETH LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,0442,365 44.2%   
Low Rs8181,625 50.3%   
Sales per share (Unadj.) Rs298.6430.3 69.4%  
Earnings per share (Unadj.) Rs57.278.7 72.7%  
Cash flow per share (Unadj.) Rs58.493.2 62.7%  
Dividends per share (Unadj.) Rs17.0020.00 85.0%  
Dividend yield (eoy) %1.81.0 182.1%  
Book value per share (Unadj.) Rs249.5586.5 42.5%  
Shares outstanding (eoy) m22.7245.75 49.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.6 67.3%   
Avg P/E ratio x16.325.3 64.2%  
P/CF ratio (eoy) x15.921.4 74.5%  
Price / Book Value ratio x3.73.4 109.7%  
Dividend payout %29.725.4 116.9%   
Avg Mkt Cap Rs m21,15791,271 23.2%   
No. of employees `0000.52.6 18.7%   
Total wages/salary Rs m4003,143 12.7%   
Avg. sales/employee Rs Th13,787.47,484.8 184.2%   
Avg. wages/employee Rs Th813.01,195.0 68.0%   
Avg. net profit/employee Rs Th2,643.31,369.1 193.1%   
INCOME DATA
Net Sales Rs m6,78319,685 34.5%  
Other income Rs m3531,143 30.9%   
Total revenues Rs m7,13620,828 34.3%   
Gross profit Rs m1,6175,003 32.3%  
Depreciation Rs m27663 4.0%   
Interest Rs m64 131.0%   
Profit before tax Rs m1,9385,479 35.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,878 33.7%   
Profit after tax Rs m1,3013,601 36.1%  
Gross profit margin %23.825.4 93.8%  
Effective tax rate %32.634.3 95.2%   
Net profit margin %19.218.3 104.8%  
BALANCE SHEET DATA
Current assets Rs m6,98424,167 28.9%   
Current liabilities Rs m2,0569,544 21.5%   
Net working cap to sales %72.674.3 97.8%  
Current ratio x3.42.5 134.2%  
Inventory Days Days9955 180.2%  
Debtors Days Days2429 83.4%  
Net fixed assets Rs m2449,514 2.6%   
Share capital Rs m227458 49.7%   
"Free" reserves Rs m5,44126,375 20.6%   
Net worth Rs m5,66826,832 21.1%   
Long term debt Rs m2525 100.0%   
Total assets Rs m7,90136,900 21.4%  
Interest coverage x353.31,305.5 27.1%   
Debt to equity ratio x00 473.4%  
Sales to assets ratio x0.90.5 160.9%   
Return on assets %16.59.8 169.2%  
Return on equity %22.913.4 171.0%  
Return on capital %34.020.4 166.8%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1522 67.9%   
Fx outflow Rs m2,6771,489 179.8%   
Net fx Rs m-2,662-1,466 181.5%   
CASH FLOW
From Operations Rs m9233,318 27.8%  
From Investments Rs m317-2,383 -13.3%  
From Financial Activity Rs m-481-1,104 43.6%  
Net Cashflow Rs m759-169 -450.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 63.9 80.0%  
Indian inst/Mut Fund % 11.3 7.5 150.7%  
FIIs % 7.2 4.9 146.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 23.7 128.3%  
Shareholders   21,978 85,207 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   IPCA LABS  GSK PHARMA  DR. DATSONS LABS  ORCHID PHARMA LTD  NOVARTIS  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY18); Net Profit Up 53.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, PFIZER has posted a net profit of Rs 1 bn (up 53.6% YoY). Sales on the other hand came in at Rs 5 bn (up 14.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS